You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

Article metrics

Article menu

This article has a correction. Please see:

XML
Clinical/translational cancer immunotherapy
Original research
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

 

Online download statistics by month:

Online download statistics by month: June 2021 to August 2025

AbstractFullPdf
Jun 2021833839315
Jul 202127127173
Aug 202119819871
Sep 202117217264
Oct 202120620691
Nov 202118618588
Dec 202123123460
Jan 202213714164
Feb 2022176200139
Mar 2022218226124
Apr 2022218232101
May 202220620983
Jun 202216318497
Jul 2022174194102
Aug 2022187191104
Sep 202219120088
Oct 2022221226114
Nov 2022222224115
Dec 202215115378
Jan 202313513577
Feb 202313013066
Mar 202317417696
Apr 202318918992
May 202313914294
Jun 202313013067
Jul 202314614683
Aug 202315215585
Sep 202310210257
Oct 202315015257
Nov 202312913171
Dec 202312712778
Jan 2024149150105
Feb 2024143143100
Mar 2024136136146
Apr 2024160161105
May 202410010186
Jun 202411611590
Jul 202413814092
Aug 2024130131147
Sep 202412412591
Oct 202412912995
Nov 2024185187135
Dec 2024202204154
Jan 2025183183106
Feb 2025176176138
Mar 2025196196166
Apr 2025256256169
May 2025245245177
Jun 202513213287
Jul 2025220
Aug 2025110
Total896791135083